Loading
A phase 2 trial of Golcadomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone in non-Hodgkin lymphoma, run by Celgene, active and no longer recruiting.
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma is a phase 2 interventional study registered as NCT06425302 by Celgene, with 95 participants enrolled, started 2024-08-30 and due to reach its primary completion in 2026-06-19. Interventions recorded: Golcadomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Prednisone, Vincristine, Rituximab, Doxorubicin and the tag pipeline.
Shares Prednisone, Vincristine, Doxorubicin, Cyclophosphamide and the tag pipeline.
Shares Prednisone, Vincristine, Rituximab, Doxorubicin and the tag pipeline.
Shares Prednisone, Rituximab, Doxorubicin, Cyclophosphamide and the tag pipeline.
Shares Prednisone, Vincristine, Rituximab, Doxorubicin and the tag pipeline.
Shares Prednisone, Rituximab, Doxorubicin, Cyclophosphamide and the tag pipeline.
Shares Golcadomide, PROTACs & molecular glues (targeted protein degradation), Vincristine, Rituximab.
Shares Prednisone, Vincristine, Doxorubicin, Cyclophosphamide and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/